Evidence map›Paper›PMID 39500794›Full record

ArticleBiochemical genetics2025

Knockdown of Inhibin Beta A Reversed the Epithelial Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Enhanced the Therapeutic Effect of Radiotherapy in Non-Small Cell Lung Cancer.

Hongfei Liu, Haiyan Zhang, Hao Yin, Gulizha Wufuer, Lei Wang, Shabiremu Abuduaini, Xuezhi Chang

Abstract read
PubMed Publisher
In one paragraph

Article in Biochemical genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hongfei LiuTumor Radiotherapy Department, Ili Kazakh Autonomous Prefecture State Friendship Hospital, Yining City, 835000, Xinjiang Province, China. drliuhongfei@hotmail.com.
Haiyan ZhangTumor Radiotherapy Department, Ili Kazakh Autonomous Prefecture State Friendship Hospital, Yining City, 835000, Xinjiang Province, China.
Hao YinTumor Radiotherapy Department, Ili Kazakh Autonomous Prefecture State Friendship Hospital, Yining City, 835000, Xinjiang Province, China.
Gulizha WufuerTumor Radiotherapy Department, Ili Kazakh Autonomous Prefecture State Friendship Hospital, Yining City, 835000, Xinjiang Province, China.
Lei WangTumor Radiotherapy Department, Ili Kazakh Autonomous Prefecture State Friendship Hospital, Yining City, 835000, Xinjiang Province, China.
Shabiremu AbuduainiTumor Radiotherapy Department, Ili Kazakh Autonomous Prefecture State Friendship Hospital, Yining City, 835000, Xinjiang Province, China.
Xuezhi ChangTumor Radiotherapy Department, Ili Kazakh Autonomous Prefecture State Friendship Hospital, Yining City, 835000, Xinjiang Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is a malignant tumor with the highest mortality rate worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately half of all lung cancer cases. Inhibin beta A (INHBA) is a ligand of the transforming growth factor-beta superfamily. This study aimed to analyze the function of INHBA in NSCLC resistance cells. Gene Expression Omnibus and The Cancer Genome Atlas databases were used to identify differentially expressed genes (DEGs) in NSCLC resistance cells and patients. DEGs were further analyzed by gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway analysis. A colony formation assay was performed to determine cell growth. Cell migration and invasion were tested by Transwell assay. Epithelial-mesenchymal transition (EMT)-related genes were analyzed using qRT-PCR and Western blot analysis. Using bioinformatics tools, INHBA was demonstrated to be overexpressed in NSCLC resistant cells and patients. Gefitinib treatment affected NSCLC resistant cells. Additionally, INHBA silencing or X-ray treatment suppressed the growth and metastasis of NSCLC resistant cells. Moreover, the combined application of INHBA silencing and X-ray treatment enhances the therapeutic effects. Moreover, EMT has been confirmed to occur in NSCLC resistant cell lines. Both INHBA silencing and X-ray treatment inhibited EMT development. This study demonstrated that INHBA silencing ameliorates EGFR-TKI resistance and enhances the therapeutic effect of radiotherapy in NSCLC.

Indexed as

Carcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmInhibin-beta SubunitsLung NeoplasmsProtein Kinase InhibitorsCell Line, TumorCell MovementCell ProliferationEpithelial-Mesenchymal TransitionErbB ReceptorsGefitinibGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansTyrosine Kinase InhibitorsEGFR protein, humanErbB ReceptorsGefitinibinhibin beta A subunitInhibin-beta SubunitsProtein Kinase InhibitorsTyrosine Kinase InhibitorsEGFR-TKI resistanceINHBANon-small cell lung cancerRadiotherapy

Identifiers

PMID39500794

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.